Vaginal Function Exercisers and Vaginal Dilation Irrigation Drug Administration Tubes Are Used for Vaginal Rehabilitation Therapy in Pelvic Radiotherapy
NCT07473271 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 76
Last updated 2026-03-16
Summary
Gynecological pelvic tumors primarily include ovarian cancer, cervical cancer, and endometrial cancer. Radiotherapy (RT) is one of the key treatment modalities for gynecological tumors. It is a necessary therapeutic approach for 80% to 90% of cervical cancer patients and 60% of endometrial cancer patients . The vagina, as a target organ and critical vulnerable organ for RT, may be affected by radiation, leading to adverse effects such as vaginal mucosal changes, adhesions, stenosis, or atresia . Vaginal stenosis (VS) is a common yet often overlooked side effect in female patients undergoing pelvic tumor RT, frequently causing symptoms such as dyspareunia, pain, vaginal dryness, or vaginal bleeding . Brand AH et al. prospectively recorded VS data from 179 cervical cancer patients receiving RT, with an average follow-up of 9.6 months, and found that 38% of patients developed VS. Park HS et al. documented VS data from endometrial cancer patients undergoing intravaginal brachytherapy, with an average follow-up of 12.9 months, and reported a VS incidence of 33%. Thais de Morais Siqueira et al. recorded subsequent VS in patients who underwent pelvic RT, with VS prevalence rates of 79% in cervical cancer patients and 67% in endometrial cancer patients. The occurrence of vaginal stenosis can impair patients' later sexual quality of life and comfort satisfaction, which is a crucial factor affecting marital relationship . Failure to prevent or address vaginal stenosis promptly may lead to psychological issues such as anxiety and depression in patients, while both physical and psychological distress can result in a decline in overall quality of life . When progressing to severe vaginal stenosis or vaginal atresia, it not only increases the discomfort during gynecological examinations but also reduces the probability of early detection of tumor recurrence, thereby affecting long-term patient survival .
Current research in China regarding the contributing factors and preventive measures for vaginal stenosis remains in the exploratory phase, with insufficient attention paid to this condition. Current clinical practice predominantly emphasizes the preventive role of vaginal irrigation against infections . During vaginal irrigation, dilators are only briefly used as a substitute for dilation. For cervical cancer patients undergoing radical radiotherapy, routine vaginal irrigation is performed both during and after the treatment. Post-radiotherapy, patients are advised to undergo routine vaginal dilation therapy.
The most commonly used method for preventing vaginal stenosis is the application of vaginal dilators or related molds. Bakker et al. demonstrated that regular use of finger dilation, vaginal dilators, or other types of dilators can improve female patients' sexual function and gradually restore normal vaginal size. Law et al. confirmed that persistent use of vaginal dilators for 6 months significantly restored vaginal size to pre-radiotherapy levels. A study investigating the use of vaginal dilators in patients undergoing pelvic tumor radiotherapy found that 80.0% of patients did not develop vaginal stenosis at 12 months post-radiotherapy, demonstrating that consistent use of vaginal dilators effectively reduces the severity of vaginal stenosis . Martins J et al. conducted a trial comparing local estrogen, local testosterone, placebo, and vaginal dilators for the prevention of vaginal stenosis (VS) in women undergoing radiotherapy for cervical cancer. After 12 months of follow-up, among 142 patients, the prevalence of VS was 11% in those treated with vaginal dilators, 57% in placebo users, and 56.8% in estrogen-treated women, confirming the efficacy of vaginal dilators in reducing VS incidence. Stahl JM et al. enrolled 243 patients who received high-dose brachytherapy (HDR) in the vagina, all of whom were treated with vaginal dilators. At 12 months, the rate of no VS occurrence was 63.5% in non-adherent patients, 70.2% in standard-adherent patients, and 81.2% in extended-adherence patients, further validating the effectiveness of persistent vaginal dilator use in reducing vaginal stenosis. Jiang Song et al. retrospectively analyzed 80 cervical cancer patients who underwent radical radiotherapy at Xuzhou Cancer Hospital from January 2017 to December 2018. The patients were divided into two groups: the control group (40 cases) received only vaginal irrigation, while the observation group (40 cases) received vaginal irrigation combined with vaginal mold application. The incidence of vaginal stenosis was compared between the two groups at 3 months post-radiotherapy. Results: The vaginal stenosis rate in the observation group was 32.50%, while that in the control group was 70.00%, with a statistically significant difference (P \<0.05). The use of vaginal mold was associated with a reduced incidence of radiation-induced vaginal stenosis in cervical cancer patients.
Conditions
- Indicated for Pelvic Radiotherapy, Vaginal Rehabilitation, and Alleviation of Late Toxic Reactions in the Vagina
Interventions
- DEVICE
-
Vaginal exerciser and vaginal dilator with irrigation tube
It is recommended to perform the procedure 2-3 times per week, with appropriate adjustments under the guidance of the investigator. In principle, it should not exceed once every other day. Each dilation session should last 10-20 minutes. For irrigation, it is suggested to use normal saline or warm water, with an irrigation volume of approximately 100-200 mL, and the procedure should be continued for 6 months.
Sponsors & Collaborators
-
Peking Union Medical College Hospital
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-01-23
- Primary Completion
- 2026-07-23
- Completion
- 2026-12-31
Countries
- China
Study Locations
More Related Trials
-
Evaluation of The Vaginal Renewal™ Program in Gynecologic Cancer Patients Experiencing Sexual Dysfunction
NCT01444911 ·Status: TERMINATED ·Phase: PHASE2
-
Quantifying Radiation Induced Vaginal Stenosis
NCT05002751 ·Status: RECRUITING
-
Promotion of Vaginal Health With CH2 Vaginal Gel After Pelvic Radiotherapy
NCT06997887 ·Status: RECRUITING ·Phase: NA
-
Feasibility of Hyivy Device Post-Radiation for Pelvic Malignancies
NCT05648253 ·Status: RECRUITING ·Phase: NA
-
Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy
NCT04094454 ·Status: RECRUITING ·Phase: NA
-
Radiation Therapy in Treating Patients With Cervical Cancer
NCT00278304 ·Status: COMPLETED ·Phase: PHASE2
-
Orcellex® Brush Versus Cervex-Brush® on Vault Smear Adequacy in Patients Treated With Radiotherapy for Cervical Cancer
NCT04461574 ·Status: UNKNOWN ·Phase: NA
-
Sexual Quality of Life of Patients With Gynecologic Cancer Treated With Brachytherapy.
NCT04184154 ·Status: COMPLETED
-
Treatment of Vaginal Atrophy With Low Intensity Nanosecond Neodymium Laser
NCT05335317 ·Status: RECRUITING ·Phase: NA
-
Vaginal Elasticity Assessment Before and After Brachytherapy/Pelvic Radiation
NCT03667859 ·Status: COMPLETED
-
MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer
NCT03634267 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies
NCT07447895 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Vaginal Radiofrequency for Vulvovaginal Atrophy in Breast Cancer Patients
NCT06900374 ·Status: RECRUITING ·Phase: NA
-
Clinical Implementation of Surface-guided Radiation Therapy in Vulvar Cancer
NCT05853549 ·Status: COMPLETED ·Phase: NA
-
Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
NCT00898352 ·Status: COMPLETED ·Phase: PHASE3
-
Fractional CO2 Laser Therapy for Survivors of Breast Malignancies
NCT03307044 ·Status: COMPLETED ·Phase: NA
-
To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT
NCT05891470 ·Status: RECRUITING ·Phase: NA
-
Identification and Prevention of Pelvic Floor Dysfunction in Gynecologic Cancer Survivors
NCT05769062 ·Status: TERMINATED ·Phase: NA
-
Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer
NCT04567771 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Photodynamic Therapy for Cervical and Vaginal Intraepithelial Neoplasia
NCT06982976 ·Status: RECRUITING ·Phase: NA
-
Vaginal Dilator Therapy Among Women With Gynecologic and Breast Cancers Experiencing Dyspareunia
NCT05129332 ·Status: WITHDRAWN ·Phase: NA
-
Comprehensive Study on the Quality of Life in Cervical Cancer Patients
NCT03967457 ·Status: UNKNOWN
-
Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients
NCT03628092 ·Status: UNKNOWN ·Phase: NA
-
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
NCT04713618 ·Status: ACTIVE_NOT_RECRUITING
-
A Novel Tapered Applicator for Vaginal Vault Brachytherapy
NCT04318340 ·Status: COMPLETED ·Phase: NA